Short-term treatment of acutely decompensated severe chronic heart failure. Levosimendan MBI 2.5 mg/ml should only be used as add-on therapy in situations where conventional therapy with e.g. diuretics, ACE-inhibitors and digitalis is not sufficient and where there is a need for inotropic support.